These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9029437)

  • 1. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor.
    Maren TH; Conroy CW; Wynns GC; Levy NS
    J Ocul Pharmacol Ther; 1997 Feb; 13(1):23-30. PubMed ID: 9029437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.
    Sugrue MF
    Prog Retin Eye Res; 2000 Jan; 19(1):87-112. PubMed ID: 10614682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological profiles of the potent carbonic anhydrase inhibitor dorzolamide hydrochloride, a topical antiglaucoma agent].
    Kobayashi M; Naito K
    Nihon Yakurigaku Zasshi; 2000 Jun; 115(6):323-8. PubMed ID: 10948564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of dorzolamide.
    Martens-Lobenhoffer J; Banditt P
    Clin Pharmacokinet; 2002; 41(3):197-205. PubMed ID: 11929320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction.
    Wong BK; Bruhin PJ; Barrish A; Lin JH
    Drug Metab Dispos; 1996 Jun; 24(6):659-63. PubMed ID: 8781782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion.
    Brechue WF; Maren TH
    Exp Eye Res; 1993 Jul; 57(1):67-78. PubMed ID: 8405174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension.
    Jansook P; Stefánsson E; Thorsteinsdóttir M; Sigurdsson BB; Kristjánsdóttir SS; Bas JF; Sigurdsson HH; Loftsson T
    Eur J Pharm Biopharm; 2010 Oct; 76(2):208-14. PubMed ID: 20637867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro.
    Hasegawa T; Hara K; Hata S
    Drug Metab Dispos; 1994; 22(3):377-82. PubMed ID: 8070313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals.
    Sugrue MF; Gautheron P; Mallorga P; Nolan TE; Graham SL; Schwam H; Shepard KL; Smith RL
    Br J Pharmacol; 1990 Jan; 99(1):59-64. PubMed ID: 2110013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.
    Kadam RS; Jadhav G; Ogidigben M; Kompella UB
    Drug Metab Dispos; 2011 Sep; 39(9):1529-37. PubMed ID: 21673129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ocular distribution of methazolamide after corneal and scleral administration: the effect of ionization state.
    Conroy CW; Maren TH
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):565-73. PubMed ID: 9867339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical drug delivery to the eye: dorzolamide.
    Loftsson T; Jansook P; Stefánsson E
    Acta Ophthalmol; 2012 Nov; 90(7):603-8. PubMed ID: 22269010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, acid-base balance and intraocular pressure effects of ethyloxaloylazolamide--a novel topically active carbonic anhydrase inhibitor.
    Sharir M; Pierce WM; Chen D; Zimmerman TJ
    Exp Eye Res; 1994 Jan; 58(1):107-16. PubMed ID: 8157096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide.
    Biollaz J; Munafo A; Buclin T; Gervasoni JP; Magnin JL; Jaquet F; Brunner-Ferber F
    Eur J Clin Pharmacol; 1995; 47(5):455-60. PubMed ID: 7720769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical and pharmacological properties of MK-927, a sulfonamide carbonic anhydrase inhibitor that lowers intraocular pressure by the topical route.
    Maren TH; Bar-Ilan A; Conroy CW; Brechue WF
    Exp Eye Res; 1990 Jan; 50(1):27-36. PubMed ID: 2307193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pH on the ocular distribution of a topical carbonic anhydrase inhibitor.
    Conroy CW; Maren TH
    Exp Eye Res; 1995 Aug; 61(2):213-22. PubMed ID: 7556485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans.
    Schmitz K; Banditt P; Motschmann M; Meyer FP; Behrens-Baumann W
    Invest Ophthalmol Vis Sci; 1999 Jun; 40(7):1621-4. PubMed ID: 10359348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring?
    Scozzafava A; Menabuoni L; Mincione F; Briganti F; Mincione G; Supuran CT
    J Med Chem; 1999 Jul; 42(14):2641-50. PubMed ID: 10411484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.
    Nesher R; Ticho U
    Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol.
    Stewart WC; Halper LK; Johnson-Pratt L; Polis A; Hartenbaum D
    J Ocul Pharmacol Ther; 2002 Jun; 18(3):211-20. PubMed ID: 12099542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.